Publication details
Heart failure and inhibition of renin-angiotensin-aldosterone system
| Authors | |
|---|---|
| Year of publication | 2018 |
| Type | Article in Periodical |
| Magazine / Source | Cor et Vasa |
| MU Faculty or unit | |
| Citation | |
| Doi | http://dx.doi.org/10.1016/j.crvasa.2018.02.003 |
| Keywords | Chronic heart failure; ACE inhibitors; Angiotensin receptor blockers; Mineralocorticoid receptor; antagonists; Aliskiren; Omapatrilat; Sacubitril/valsartan (LCZ 696) |
| Description | A historical survey is presented of mortality clinical trials focussed on the inhibition of the renin-angiotensin-aldosterone system on different levels in patients with chronic heart failure. The first study, CONSENSUS, was published in 1987 and showed that the ACE-inhibitor enalapril clearly reduced mortality in severe heart failure compared with placebo. This was followed by studies with beta blockers, angiotensin II type 1 receptor blockers, blockers of mineralocorticoid receptors, and direct renin inhibitors. A recent study, PARADIGM, comparing dual inhibitor of neprilysin and antiotensin II receptor (LCZ 696) with enalapril, was terminated prematurely for a significant effect of inhibiting neprilysin and valsartan. (C) 2018 The Czech Society of Cardiology. Published by Elsevier Sp. z o.o. All rights reserved. |